Search
Sulbactam
go.drugbank.com/drugs/DB09324ApprovedInvestigational[L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296] … Sulbactam is a beta (β)-lactamase inhibitor and a derivative of the basic penicillin nucleus.
Mixtures: SULPERAZON 1G IM/IV, UNASYN IM/IV 1.5GProducts: B-LAKTAM 1 GR IM/IV ENJEKTABL TOZ ICEREN FLAKON, 5 ADET, B-LAKTAM 1 GR IM/IV ENJEKTABL TOZ ICEREN FLAKON, 100 ADETGranisetron
go.drugbank.com/drugs/DB00889ApprovedInvestigationalA serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Products: AXIGRAN 1MG/ML KON INJ INF, KYTRIL 3MG/3ML INJ LSGCyanocobalamin
go.drugbank.com/drugs/DB00115ApprovedInvestigationalNutraceuticalThis drug was initially approved by the FDA in 1942 [FDA label]. … The _cyano_ form, is the most widely used form in supplements and prescription drugs [A175255], [FDA label].
Mixtures: Multi II IV Vi Tab, Vc IIProducts: Cobex Inj 1000mcg/ml, Vitamin B12 Inj 100mcg/mlBenralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigationalIt is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells, macrophages and neutrophils. … [A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction.
Products: Fasenra 30 mg solution for injection in pre-filled syringe, Fasenra 30mg Solution for Injection in Pre-filled PenPamidronic acid
go.drugbank.com/drugs/DB00282ApprovedInvestigationalPamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977. … [A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835]
Products: PAMEX 90 MG IV INF. ICIN LIYOFILIZE TOZ ICEREN FLAKON, 1 ADET, Aredia Liq Inj 3mg/mlProtein C
go.drugbank.com/drugs/DB11312ApprovedInvestigationalProtein C is available in concentrated form as the product Ceprotin, which is indicated for use in pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment … Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETProducts: CEPROTIN 500 IU IV ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ İÇEREN FLAKONFremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment
Products: AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5ML, AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225 MG/1.5MLInterferon beta-1a
go.drugbank.com/drugs/DB00060ApprovedInvestigationalIt is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. … The amino acid sequence is identical to that of natural human interferon beta.
Categories: Interferon Type ISynonyms: IFN-β1a, IFN β-1aLixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).
Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/MLCategories: Drugs Used in DiabetesDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigational[A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular … therapy to diet and exercise in the management of 2 diabetes (T2DM).
Categories: Drugs Used in DiabetesProducts: Trulicity 1.5mg solution for injection in pre-filled pen, Trulicity 0.75mg solution for injection in pre-filled pen